Risk stratification and prevention of sudden death in hypertrophic cardiomyopathy

[1]  M. Link,et al.  Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. , 2007, JAMA.

[2]  W. Manning,et al.  Prevalence, Clinical Profile, and Significance of Left Ventricular Remodeling in the End-Stage Phase of Hypertrophic Cardiomyopathy , 2006, Circulation.

[3]  C. Autore,et al.  Management of hypertrophic cardiomyopathy , 2006, BMJ : British Medical Journal.

[4]  G. Boriani,et al.  Dilated-hypokinetic evolution of hypertrophic cardiomyopathy: prevalence, incidence, risk factors, and prognostic implications in pediatric and adult patients. , 2005, Journal of the American College of Cardiology.

[5]  Michael Jerosch-Herold,et al.  Utility of Cardiac Magnetic Resonance Imaging in the Diagnosis of Hypertrophic Cardiomyopathy , 2005, Circulation.

[6]  J. Seidman,et al.  Glycogen storage diseases presenting as hypertrophic cardiomyopathy. , 2005, The New England journal of medicine.

[7]  G. Boriani,et al.  Prevention of Sudden Death in Hypertrophic Cardiomyopathy: But Which Defibrillator for Which Patient? , 2004, Circulation.

[8]  J. Hodgson,et al.  Urinary 20-Hydroxyeicosatetraenoic Acid Is Associated With Endothelial Dysfunction in Humans , 2004, Circulation.

[9]  Barry J Maron,et al.  American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice G , 2003, Journal of the American College of Cardiology.

[10]  P. Elliott,et al.  Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. , 2003, Journal of the American College of Cardiology.

[11]  M. Link,et al.  Primary prevention of sudden death as a novel treatment strategy in hypertrophic cardiomyopathy. , 2003, Circulation.

[12]  D. Pennell,et al.  Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. , 2003, Journal of the American College of Cardiology.

[13]  B. Maron,et al.  Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. , 2003, The New England journal of medicine.

[14]  B. Maron.  Hypertrophic cardiomyopathy: a systematic review. , 2002, JAMA.

[15]  J. Seidman,et al.  The Genetic Basis for Cardiomyopathy from Mutation Identification to Mechanistic Paradigms , 2001, Cell.

[16]  P. Elliott,et al.  Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy , 2001, The Lancet.

[17]  P. Elliott,et al.  Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. , 2000, Journal of the American College of Cardiology.

[18]  B. Maron,et al.  Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. , 2000, The New England journal of medicine.

[19]  M. Link,et al.  Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. , 2000, The New England journal of medicine.

[20]  W. Mckenna,et al.  Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy. , 1997, Circulation.

[21]  W. Mckenna,et al.  The management of hypertrophic cardiomyopathy. , 1997, The New England journal of medicine.

[22]  R. Bonow,et al.  Occurrence and significance of progressive left ventricular wall thinning and relative cavity dilatation in hypertrophic cardiomyopathy. , 1987, The American journal of cardiology.